Search clinical trials for: Tapentadol extended release (ER)

Total 779 results

Alkermes, Inc.

Completed

ALK21-010: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol-dependent Adults

Alcoholism
Alkermes, Inc.

Terminated

ALK21-006EXT: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol- or Opioid-dependent Adults (Extension of Study ALK21-006 [NCT01218997])

Alcoholism | Opiate Dependence
Adamas Pharmaceuticals, Inc.

Completed

A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

Multiple Sclerosis | Walking Impairment

United States, Canada
GlaxoSmithKline

Completed

Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa

Epilepsy

United States
The Rogosin Institute

Terminated

Combined Renin Inhibition/Beta-blockade

Hypertension

United States
Merck Sharp & Dohme LLC

Completed

Merck Carotid Atherosclerosis Trial (MK-0000-111)(COMPLETED) (MCAT)

Carotid Atherosclerosis
New York State Psychiatric Institute
National Institute of Mental Health (NIMH)

Completed

Improving Retention of Hispanics Receiving Antidepressant Therapy

Depressive Disorder | Depression

United States
AstraZeneca

Completed

Quetiapine Extended Release Depression Symptoms (ExAttitude)

Depression | Schizophrenia

Italy
Alkermes, Inc.

Completed

ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®)

Alcoholism
Bangabandhu Sheikh Mujib Medical University, Dhaka...

Completed

Serum Creatinine Change / Renal Adverse Effect With Use of Non-steroidal Painkillers in Axial Spondyloarthritis Patients

Axial Spondyloarthritis
University of Pennsylvania
Alkermes, Inc.

Recruiting

Naltrexone in AUD Reward Drinkers

Alcoholism | Alcohol Use Disorder

United States
Food and Drug Administration (FDA)
Algorithme Pharma Inc; Vince & Associates Clinical Research, Inc.

Completed

A Bioavailability Crossover Study of Two Formulations of Lamotrigine Extended Release Tablets in Healthy Subjects

Healthy

United States
Adamas Pharmaceuticals, Inc.

Completed

Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

Multiple Sclerosis | Walking Impairment

United States
Emory University
Bristol-Myers Squibb

Completed

Nefazodone in the Treatment of Social Phobia

Social Anxiety Disorder (SAD)

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-release Paliperidone in Subjects With Bipolar I Disorder

Mood Disorders | Bipolar Disorder
Ranbaxy Laboratories Limited

Completed

Bioequivalence Study on Pseudoephedrine HCl 120 mg ER Tablets Under Fasting Conditions

Healthy

Canada
Depomed

Completed

Safety and Efficacy of Gabapentin in Postherpetic Neuralgia

Neuralgia, Postherpetic

United States
Hennepin Healthcare Research Institute
Medical University of South Carolina; Massachusetts General Hospital; Northwestern... and other collaborators

Enrolling by invitation

Free Samples for Health (FreSH)

Cigarette Smoking

United States
Shire

Completed

Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Spain, United States, Germany, Poland, Italy, Ukraine, Romania, United Kingdom, Sweden, Austria, Canada, France, Ireland
Centre Hospitalier Universitaire de Tivoli

Completed

Sufentanil Sublingual Tablet System for Postoperative Pain Management After Total Knee Arthroplasty

Postoperative Pain

Belgium
Depomed

Completed

Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women (Breeze3)

Hot Flashes

United States
Johns Hopkins University
National Institute on Drug Abuse (NIDA)

Completed

The Role of Sleep in the Treatment of Cannabis Use Disorders

Drug Addiction

United States
Edgemont Pharmaceuticals, LLC

Completed

EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD)

Generalized Anxiety Disorder (GAD)

United States
H. Lundbeck A/S
Otsuka Pharmaceutical Co., Ltd.

Completed

Brexpiprazole in Patients With Acute Schizophrenia

Schizophrenia

United States
GlaxoSmithKline

Completed

Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Partial Seizures

Epilepsy | Epilepsy, Partial

United States, Germany, Korea, Republic of, Chile, India, Russian Federation, Brazil, Ukraine, Puerto Rico, Argentina
Depomed

Completed

Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women

Hot Flashes

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Effect of Food and Posture on the Pharmacokinetics of a Single Dose of ER OROS Paliperidone

Schizophrenia
Actavis Inc.

Completed

A Relative Bioavailability Study of Alprazolam 3 mg Extended Release Tablets Under Non-fasting Conditions

Healthy

United States
Kos Pharmaceuticals

Completed

The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC

Intermittent Claudication | Peripheral Vascular Disease

United States
Nang Kuang Pharmaceutical Co., Ltd.

Recruiting

A Phase I Study to Evaluate the Safety and PK of ND-340 in Healthy Volunteers

Pain, Postoperative

Taiwan
Kathmandu University
Asian Pharmaceuticals Pvt. Ltd.

Active, not recruiting

Bioequivalence Study of Sodium Valproate and Valproic Acid Tablets (BA-BE)

Epilepsy

Nepal
Shire

Completed

Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to Asacol 0.8g Three Times Daily in Subjects With Acute, Mild to Moderate Ulcerative Colitis

Ulcerative Colitis

Belgium
Adamas Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia (EASE LID 3)

Parkinson's Disease (PD) | Dyskinesia | Levodopa-Induced Dyskinesia (LID)

France, Spain, United States, Germany, Austria
Supernus Pharmaceuticals, Inc.
Parexel

Completed

Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1)

Epilepsies, Partial

United States, Poland, Mexico, Bulgaria, Romania, Canada, Russian Federation, Croatia
Actavis Inc.

Completed

A Relative Bioavailability Study of Alprazolam 3 mg ER Tablets Under Fasting Conditions

Healthy

United States
Kos Pharmaceuticals

Completed

Effect of Niacin ER/Lovastatin on Peak Walking Time & Claudication Onset Time in Patients With Intermittent Claudication

Intermittent Claudication | Peripheral Vascular Disease
Rhode Island Hospital

Recruiting

Combined Injectable Treatment for HIV and OUD (CHOICE)

Opioid Use Disorder | Human Immunodeficiency Virus

United States
Cairo University
Ahmed Elgazzar Hospital

Completed

Extended High Dose Letrozole Regimen Versus Short Low Dose Letrozole Regimen as an Adjuvant to GnRH Antagonist Protocol in the Management of Poor Responders Undergoing IVF-ET

Infertility

Egypt
Seattle Children's Hospital
Children's Hospital of Philadelphia

Not yet recruiting

Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity

Craniopharyngioma | Hypothalamic Obesity | Hypothalamic Tumor

United States
Galenicum Health

Completed

Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.

Diabetes Mellitus, Type 2 | Bioequivalence

Mexico
Galenicum Health

Completed

Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.

Diabetes Mellitus, Type 2 | Bioequivalence

Mexico
NYU Langone Health
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC

Completed

Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment

Opioid Use Disorder

United States
University of Alabama at Birmingham
Pfizer

Completed

Detrol Long Acting (LA) vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms (DRIVE)

Overactive Bladder
Janssen Korea, Ltd., Korea

Completed

Phase 4 Study to Evaluate Efficacy of Paliperidone Extended-Release(ER) in Schizophrenic Participants (PASS)

Schizophrenia

Korea, Republic of
Janssen Korea, Ltd., Korea

Completed

Efficacy Study of Paliperidone to Evaluate Subjective Change in Well-being and Drug Attitude in Schizophrenic Participants (Power)

Schizophrenia

Korea, Republic of
Depomed

Completed

Safety and Efficacy of Gabapentin in Diabetic Peripheral Neuropathy

Diabetic Peripheral Neuropathy
UCB Pharma

Completed

Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed Epilepsy

Epilepsy

Australia, France, Germany, Italy, Poland, United Kingdom, Belgium, Spain, Switzerland, Austria, Bulgaria, Romania, Turkey, Denmark, Greece, Russian Federation, Netherlands, Hungary, Ireland, Slovakia, Sweden, Norway, Finland, Czech Republic
Duke University
National Institute of Mental Health (NIMH)

Completed

Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)

Attention Deficit Disorder With Hyperactivity

United States
Kasr El Aini Hospital

Completed

Low Dose Tadalafil for Treatment of Female OAB Syndrome: Short Term Follow up.

Female Patients With Overactive Bladder Syndrome or Female Patients With Urgency or Urgency Urinary Incontinence

Egypt
Indiana University

Completed

Endoscopic Ultrasound (EUS)-Guided Ablation of Pancreatic Cysts

Pancreatic Cyst | Pancreatic Intraductal Papillary-Mucinous Neoplasm | Cystadenoma, Mucinous | Papillary Mucinous Cystadenoma, Borderline Malignancy

United States

Search clinical trials for: Tapentadol extended release (ER)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations